4D Molecular Therapeutics Cash And Cash Equivalents And Marketable Securities Were $218.5M As Of December 31, 2022, As Compared To $315.4M As Of December 31, 2021
Full Year 2022 Financial Results
Cash and Cash Equivalents and Marketable Securities: Cash and cash equivalents and marketable securities were $218.5 million as of December 31, 2022, as compared